The Federal Trade Commission (FTC) is considering conducting a study to analyze the use and likely short- and long-run competitive effects of authorized generic drugs in the prescription drug marketplace. An authorized generic is chemically identical to a particular brand-name drug, but the brand-name manufacturer authorizes it to be marketed in a generic version. In […]
In an Op-Ed piece in the New York Times entitled “Patently Ridiculous,” the editors state that “something has gone very wrong with the United States patent system. That’s not really “new” as far as patent reform claims of this sort go but the editors do finally concede that the problem lies “not just with the […]
There are a lot of blogs in the world so I tend to cringe when I see another one (I don’t want to have to keep up with yet more information). But, I’ll just mention a new collaborative law blog, named Blawgr, that was set loose last month as the brainchild of Stephen Nipper, Doug […]
Forbes ran an interesting article about Genentech that shows how it pursues a different path than traditional Big Pharma companies like Pfizer and Merck, which market drugs to the masses. Genentech takes a very different approach by foregoing mass-market medicines in favor of drugs specific for severe diseases even if that limits the market potential. […]
In some other news of kudos for out site, TopTenSources has selected Patent Baristas to be a featured Top 10 Source site. Top 10 Sources publishes a daily “Top 10” site of the best newsfeeds on the Internet. Their editors pick a topic then find the ten best sources on the Net on that topic […]
… and good will to all!
The U.S. House of Representatives approved $3.78 billion prepare for a possible avian flu epidemic, including stockpiling potential vaccines, training emergency officials and increasing international surveillance. At the last minute, an unrelated provision (called the Public Readiness and Emergency Preparedness Act) to protect vaccine, drug and medical device makers against lawsuits in a public health […]
AstraZeneca New Zealand announced that it has reached an oral agreement with the New Zealand government drug-buying agency to continue supplying its prostate and breast cancer medicine Zoladex to the New Zealand market, ending a bad public relations nightmare for both the company and the New Zealand government. AstraZeneca earlier made the decision to withdraw […]
Served Up Daily
Editor-in-Chief Barista Stephen Jenei is a patent attorney and Owner of Jenei LLC. When not serving up patent chat over a steaming cup of java, he's handling a diverse intellectual property practice in the biotechnology, pharmaceutical and chemical fields. More info @ Jenei LLC
